Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

X4 Pharmaceuticals Inc (XFOR)

X4 Pharmaceuticals Inc (XFOR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

X4 Pharmaceuticals Inc 61 North Beacon Street 4th Floor Boston MA 02134 USA

www.x4pharma.com Employees: 143 P: 857-529-8300

Sector:

Medical

Description:

X4 Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel therapeutics for the treatment of rare diseases. The company's product candidates include X4P-001, X4P-002 and X4P-003 which are in clinical stage. X4 Pharmaceuticals Inc., formerly known as Arsanis, Inc., is based in Cambridge, United States.

Key Statistics

Overview:

Market Capitalization, $K 386,472
Enterprise Value, $K 406,202
Shares Outstanding, K 87,437
Annual Sales, $ 2,560 K
Annual Net Income, $ -37,450 K
Last Quarter Sales, $ 1,770 K
Last Quarter Net Income, $ -29,820 K
EBIT, $ -98,900 K
EBITDA, $ -98,100 K
60-Month Beta 0.42
% of Insider Shareholders 2.37%
% of Institutional Shareholders 72.03%
Float, K 85,365
% Float 97.63%
Short Interest 2,482
Short Float 2.84%
Short Volume Ratio 0.80

Growth:

1-Year Return -82.00%
3-Year Return -85.16%
5-Year Return -97.71%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 84.67%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.69 on 11/05/25
Next Earnings Date 03/24/26
Earnings Per Share ttm -10.13
EPS Growth vs. Prev Qtr 80.12%
EPS Growth vs. Prev Year 87.23%
Annual Dividend & Yield 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%
Most Recent Split 1-30 on 04/28/25

XFOR Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -343.67%
Return-on-Assets % -69.77%
Profit Margin % -1,462.89%
Debt/Equity 1.23
Price/Sales 140.88
Price/Cash Flow N/A
Price/Book 1.68
Book Value/Share 2.45
Interest Coverage -3.23
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar